{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:24:56Z","timestamp":1789809896794,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.biopha.2014.01.009","type":"journal-article","created":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T10:31:05Z","timestamp":1391769065000},"page":"343-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"68","author":[{"given":"Anthony","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Aziz Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Sim","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Abdul","family":"Wahid Fadilah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Rosline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Ankathil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2014.01.009_bib0005","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2014.01.009_bib0010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2005-10-4020","article-title":"Complex interaction of BCRP\/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression","volume":"108","author":"Nakanishi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2014.01.009_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","article-title":"Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects","volume":"69","author":"Cascorbi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopha.2014.01.009_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendation for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.biopha.2014.01.009_bib0025","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2014.01.009_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200104000-00005","article-title":"MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity","volume":"11","author":"Ameyaw","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopha.2014.01.009_bib0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.104.001628","article-title":"Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta","volume":"33","author":"Kobayashi","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.biopha.2014.01.009_bib0040","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.biopha.2014.01.009_bib0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2404897","article-title":"Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2","volume":"22","author":"Shukla","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2014.01.009_bib0050","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/sj.leu.2404671","article-title":"Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels","volume":"21","author":"Widmer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2014.01.009_bib0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exphem.2005.03.014","article-title":"RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines","volume":"33","author":"Rumpold","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.biopha.2014.01.009_bib0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.7763\/IJESD.2012.V3.230","article-title":"Influence of ABCB1 C3435T and ABCG2 C421A gene polymorphisms in response to imatinib mesylatein chronic myeloid leukemia patients","volume":"3","author":"Anthony","year":"2012","journal-title":"Int J Environ Sci Dev"},{"key":"10.1016\/j.biopha.2014.01.009_bib0065","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2014.01.009_bib0070","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2010-08-298794","article-title":"Is there really a relationship between Multidrug resistance gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia","volume":"116","author":"Dulucq","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2014.01.009_bib0075","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1182\/blood-2010-07-296954","article-title":"Polymorphisms in the Multidrug Resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia (CML) receiving high dose imatinib","volume":"116","author":"Deenik","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2014.01.009_bib0080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.biopha.2014.01.009_bib0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clpt.2005.11.013","article-title":"MDR1 genotype is associated with hepatic cytochrome P4503A4 basal land induction phenotype","volume":"79","author":"Lamba","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopha.2014.01.009_bib0090","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2014.01.009_bib0095","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2014.01.009_bib0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J Hum Genet"},{"issue":"3","key":"10.1016\/j.biopha.2014.01.009_bib0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FPC.0b013e328350012b","article-title":"MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression","volume":"22","author":"Turrini","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.biopha.2014.01.009_bib0110","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jps.23436","article-title":"Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP\/ABCG2): effect of age, sex, and genotype","volume":"102","author":"Prasad","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.biopha.2014.01.009_bib0115","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","article-title":"Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib","volume":"80","author":"Gardner","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopha.2014.01.009_bib0120","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults","volume":"14","author":"Petain","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2014.01.009_bib0125","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2014.01.009_bib0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1248\/bpb.34.114","article-title":"Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia","volume":"34","author":"Nambu","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.biopha.2014.01.009_bib0135","first-page":"244","article-title":"Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia","volume":"33","author":"Yamakawa","year":"2011","journal-title":"Ther Drug Monit"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332214000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332214000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:52:56Z","timestamp":1760093576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332214000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0753332214000201"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2014.01.009","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2014.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}